Table 2.
Demographic and clinical data.
| NR | SEX | AGE | ONSET | RE | LE | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCVA | VF | EZ | CS | Grade | BCVA | VF | EZ | CS | Grade | |||||
| USH2A | 1 | F | 21 | 8 | 0 | 2 | 3 | 5 | 2 | 0 | 2 | 3 | 5 | 2 |
| 2 | F | 59 | 16 | 5 | 5 | 5 | 15 | 5 | 4 | 5 | 5 | 14 | 5 | |
| 3 | F | 62 | 25 | 5 | 5 | 5 | 15 | 5 | 5 | 5 | 5 | 15 | 5 | |
| 4 | M | 18 | 13 | 1 | 1 | 5 | 7 | 3 | 1 | 1 | 5 | 7 | 3 | |
| 5 | M | 49 | 30 | 3 | 5 | 5 | 13 | 5 | 3 | 5 | 5 | 13 | 5 | |
| 6 | F | 21 | 19 | 3 | 0 | 4 | 7 | 3 | 1 | 0 | 4 | 5 | 2 | |
| 7 | M | 17 | 15 | 0 | 0 | 2 | 2 | 1 | 0 | 0 | 2 | 2 | 1 | |
| 8 | M | 48 | 18 | 3 | 5 | 4 | 12 | 4 | 3 | 5 | 5 | 13 | 5 | |
| 9 | F | 27 | 21 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | |
| 10 | M | 32 | 22 | 0 | 0 | 5 | 5 | 2 | 0 | 1 | 5 | 6 | 2 | |
| 11 | M | 31 | 20 | 0 | 1 | 3 | 4 | 2 | 0 | 0 | 4 | 4 | 2 | |
| 12 | M | 55 | 54 | 0 | 1 | 5 | 6 | 2 | 0 | 1 | 5 | 6 | 2 | |
| 13 | F | 36 | 17 | 3 | 1 | 5 | 9 | 3 | 2 | 1 | 5 | 8 | 3 | |
| 14 | M | 62 | 20 | 4 | 5 | 5 | 14 | 5 | 4 | 5 | 5 | 14 | 5 | |
| 15 | F | 47 | 44 | 4 | 5 | 5 | 14 | 5 | 4 | 5 | 5 | 14 | 5 | |
| 16 | F | 30 | 23 | 0 | 3 | 2 | 5 | 2 | 0 | 2 | 2 | 4 | 2 | |
| 17 | M | 42 | 15 | 3 | 5 | 5 | 13 | 5 | 4 | 5 | 5 | 14 | 5 | |
| 18 | M | 55 | 25 | 5 | 3 | 5 | 13 | 5 | 4 | 4 | 5 | 13 | 5 | |
| 19 | F | 59 | 58 | 0 | 2 | 1 | 3 | 1 | 0 | 2 | 1 | 3 | 1 | |
| 20 | M | 72 | 43 | 4 | 2 | 5 | 11 | 4 | 4 | 1 | 5 | 10 | 4 | |
| NSRP | 21 | M | 38 | 37 | 3 | 0 | 4 | 7 | 3 | 4 | 0 | 4 | 8 | 3 |
| 22 | F | 52 | 20 | 3 | 3 | 5 | 11 | 4 | 3 | 3 | 5 | 11 | 4 | |
| 23 | F | 35 | 12 | 1 | 3 | 4 | 8 | 3 | 1 | 2 | 4 | 7 | 3 | |
BCVA: best-corrected visual acuity; CS: cumulative score; EZ: ellipsoid zone; F: female; LE: left eye; M: male; N: number; NSRP: non-syndromic retinitis pigmentosa; RE: right eye; USH2A; Usher syndrome (USH) with variants in USH2A gene; VF: visual field.